Monitoring of monoclonal antibodies for COVID-19: weekly report published

AIFA defines criteria for use of Paxlovid soon available in Italy

Monitoring of oral antivirals for COVID-19: second report published

Monitoring of monoclonal antibodies for COVID-19: weekly report published

COVID-19: EMA recommends conditional marketing authorisation for Paxlovid

Rapporto annuale sulla Sorveglianza dei vaccini COVID-19

Monitoring of oral antivirals for COVID-19: first report published

Monitoring of monoclonal antibodies for COVID-19: weekly report published

COVID-19: latest safety data provide reassurance about use of mRNA vaccines during pregnancy

Preliminary data indicate COVID-19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron variant

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 January 2022

Modifiche Registri - VEKLURY (trattamento precoce), mABs e antivirali orali Covid-19 (lagevrio)

AIFA: no effective antibiotics against COVID-19

Monitoring of monoclonal antibodies for COVID-19: weekly report published

EMA receives application for conditional marketing authorisation for Paxlovid for treating patients with COVID-19

AIFA approves Comirnaty booster dose for 12-15 year olds

Monitoring of monoclonal antibodies for COVID-19: weekly report published

Attivazione web e pubblicazione schede di monitoraggio - Registro VEKLURY Trattamento precoce - COVID-19

Attivazione web e pubblicazione schede di monitoraggio - Registro Antivirali orali COVID-19 - LAGEVRIO (MOLNUPIRAVIR)

Monitoring of monoclonal antibodies for COVID-19: weekly report published